US FDA Accepts for Review Biohaven's New Drug Application (NDA) Filing of Intranasal Zavegepant for the Acute Treatment of Migraine

/PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the U.S. Food and Drug Administration (FDA) has filed and...

Related Keywords

,Richardb Lipton ,Jennifer Porcelli ,Mike Beyer ,Biohaven Neuroinnovation ,Exchange Commission On ,Albert Einstein College Of Medicine ,World Health Organization ,Drug Administration ,Montefiore Headache Center ,Sam Brown Inc ,Biohaven Pharmaceutical Holding Company Ltd ,Exchange Commission ,Prnewswire Biohaven Pharmaceutical Holding Company Ltd ,Pharmaceutical Holding Company ,New Drug Application ,Prescription Drug User Fee Act ,Chief Executive Officer ,Vice Chair ,Albert Einstein College ,Chief Medical Officer ,Migraine Platform ,Biohaven Pharmaceutical Ireland ,Biohaven Pharmaceutical Holding Company ,Private Securities Litigation Reform Act ,Annual Report ,